COVID-19 pandemic with SARS-CoV-2 infection has become a global challenge. Though most cases of COVID-19 are mild, the disease can also be fatal. Patients with liver cirrhosis are more susceptible to damage from SARS-CoV-2 infection considering their immunocompromised status. The spectrum of disease and factors that influence the disease course in COVID-19 cases with liver cirrhosis are incompletely defined. This muilticentre observational study (COVID-Cirrhosis-CHESS2002) aims to study the clinical characteristics and risk factors associated with specific outcomes in COVID-19 patients with pre-existing liver cirrhosis.
Coronavirus disease 2019 (COVID-19) pandemic with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has become a global challenge. Though most cases of COVID-19 are mild, the disease can also be fatal. Patients with liver cirrhosis are more susceptible to damage from SARS-CoV-2 infection considering their immunocompromised status. The spectrum of disease and factors that influence the disease course in COVID-19 cases with liver cirrhosis are incompletely defined. This muilticentre observational study (COVID-Cirrhosis-CHESS2002) aims to study the clinical characteristics and risk factors associated with specific outcomes in COVID-19 patients with pre-existing liver cirrhosis.
Study Type
OBSERVATIONAL
Enrollment
21
Dalian Sixth People's Hospital
Dalian, China
Minda Hospital Affiliated to Hubei University for Nationalities
Enshi, China
The Central Hospital of Enshi Tujia And Miao Autonomous Prefecture
Enshi, China
The First Hospital of Lanzhou University
Lanzhou, China
The Central Hospital of Lishui City
Lishui, China
Guangxi Zhuang Autonomous Region
Nanning, China
The Sixth Peoples Hospital of Shenyang
Shenyang, China
Shenzhen Third People's Hospital
Shenzhen, China
Suizhou Hospital, Hubei University of Medicine
Suizhou, China
Tianjin Second People's Hospital
Tianjin, China
...and 5 more locations
All-cause mortality of COVID-19 patients with liver cirrhosis
7-day, 28-day, 60-day, 180-day and 365-day all-cause mortality of COVID-19 patients with liver cirrhosis
Time frame: From illness onset of COVID-19 to death from any cause, up to 365 days
Liver-related mortality of COVID-19 patients with liver cirrhosis
7-day, 28-day, 60-day, 180-day and 365-day liver-related mortality of COVID-19 patients with liver cirrhosis
Time frame: From illness onset of COVID-19 to death from liver-related cause, up to 365 days
Risk factors associated with specific outcomes of COVID-19 patients with liver cirrhosis
Risk factors (laboratory findings, imaging findings, etc.) associated with specific outcomes (death, etc.) of COVID-19 patients with liver cirrhosis
Time frame: From hospital admission to death, up to 365 days
Baseline characteristics of COVID-19 patients with liver cirrhosis
Baseline characteristics (laboratory findings, imaging findings, etc.) of COVID-19 patients with liver cirrhosis
Time frame: 1 Day
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.